article · Minia Journal of Medical Research
Background: Sepsis was a major factor in mortality inside intensive care units (ICU) worldwide. There was a paucity of knowledge about early markers that may forecast mortality and morbidity. This research aimed to assess the efficacy of Clinical Scores in predicting death among septic patients in the ICU. Methodology: This prospective clinical research included 91 patients of both genders, aged over 20, who presented to the ICU with serious infections or developed sepsis while in the ICU. The primary result was mortality among the examined patients; scores assessed upon admission constituted the secondary outcome. Demographic and clinical data were gathered at the trial's commencement. Results: Among 91 ICU patients diagnosed with severe sepsis, the overall death rate was 63%. Non-survivors had markedly elevated clinical scores, including APACHE II (median 29 vs. 17), SOFA (median 12 vs. 9), and NUTRIC (median 8 vs. 2), in comparison to survivors (p < 0.001). Optimal cutoff values for mortality prediction were >20 for APACHE II, with 100% sensitivity and 91% specificity; >9.5 for SOFA, exhibiting 98% sensitivity and 97% specificity; and >3.5 for NUTRIC, with 100% sensitivity and 94% specificity. Conclusion: The research indicated a mortality rate of 63% in individuals diagnosed with severe infection. Individuals with severe sepsis exhibiting an APACHE II score above 25, a SOFA score surpassing 8.5, and a NUTRIC score more than 5 at ICU admission had an elevated mortality risk.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/mjmr.2024.267252.1655
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.